The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Neuromyelitis optica (NMO), also known as Devic's disease, is an autoimmune, inflammatory disorder of the central nervous system (CNS) in which the immune system attacks myelin of the neurons located at the optic nerves and spinal cord, thus producing a simultaneous or sequential optic neuritis and myelitis. The objective of this study was evaluated the background T-cell function of patients suffering from neuromyelitis optica (NMO), an autoimmune disorder of the central nervous system. In our study, the in vitro T cell proliferation and the production of Th1 cytokines were significantly lower in cell cultures from NMO patients, as compared with healthy individuals. In contrast, a dominant Th17-like phenotype, associate with higher IL-23 and IL-6 production by LPS-activated monocytes, was observed among NMO patients. The release of IL-21 and IL-6 by polyclonally activated CD4+ T cells was directly correlated to neurological disability. In addition, the in vitro release of IL-21, IL-6 and IL-17 was significantly more resistant to glucocorticoid inhibition in NMO patients. In conclusion, the results indicate dominant Th17-related response in NMO patients that was directly proportional to neurological disability. Furthermore, our results can help to explain why NMO patients trend to be more refractory to corticoid treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies in AIDs, including NMOSD, mainly identify T cells with pro-inflammatory or B cell helper function. 16,24-31”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [25]
In the citing paper
“Auto-Th cells with a pro-inflammatory or B cell helper profile are seen in AID patients, 16,24-31 but comprehensive ex vivo analyses are missing.”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [25]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
Lucchinetti, C. F. (2002) · Brain · doi:10.1093/brain/awf151 · Cited by 1,210
Jovanović, D., Battista, J. A. D., Pelletier, J., Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F., & Martel‐Pelletier, J. (1998) · PubMed · Cited by 973
Research works printed but not linked: 3
- Devic E. Myélite aiguë dorse-lombaire de névrite optique, autopsie. Congress Français de méd. Premiere Seance. 1984;9:434–9.
- Wingerchuk DM, Hogancamp WF, O’brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–14. · DOI · Paper page
- Matsuya N, Komori M, Nomura K, Nakane S, Fukudome T, Goto H, Shiraishi H, Wandinger KP, Matsuo H, Kondo T. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol. 2011;23(9):565–73. · DOI · Paper page
Cited by
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12271 · Cited by 342
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Carnero Contentti, E., & Correale, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 338
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.141 · Cited by 262
Glucocorticoids in T cell development, differentiation and function
Taves, M. D., & Ashwell, J. D. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00464-0 · Cited by 225
Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models
Wu, Y., Zhong, L., & Geng, J. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.12.002 · Cited by 160
dos Passos, G. R., Sato, D. K., Becker, J., & Fujihara, K. (2016) · Mediators of Inflammation · doi:10.1155/2016/5314541 · Cited by 171
“Further studies are required to clarify if cytokine levels are useful to indicate disease activity and if interference in the Th17 pathway can reduce inflammation in the CNS during relapses.”
BackgroundWilson, R., Makuch, M., Kienzler, A., Varley, J. A., Taylor, J., Woodhall, M. R., Palace, J. A., Leite, M. I., Waters, P. J., & Irani, S. R. (2018) · Brain · doi:10.1093/brain/awy010 · Cited by 123
Riedhammer, C., & Weissert, R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00322 · Cited by 117
“Nevertheless, T cells seem to be mandatory for the initial emergence of plasma cells which secrete AQP-4-specific antibodies (242, 243).”
BackgroundCytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications
Uzawa, A., Masahiro, M., & Kuwabara, S. (2013) · Brain Pathology · doi:10.1111/bpa.12097 · Cited by 110
“The release of IL-6, IL-21 and IL-23 from activated peripheral blood mononuclear cells is significantly higher in NMO patients than in controls, and IL-6 and IL-21 levels positively correlate with the EDSS score in NMO patients (28).”
BackgroundBarros, P. O., Cassano, T., Hygino, J., Ferreira, T. B., Centurião, N., Kasahara, T. M., Andrade, R. M., Linhares, U. C., Andrade, A. F. B., Vasconcelos, C. C. F., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12733 · Cited by 86
Self-citationFollicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal Models
Fan, X., Lin, C., Han, J., Jiang, X., Zhu, J., & Jin, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/638968 · Cited by 81
“Consistent with this, another study showed that the release of IL-21 by peripheral blood mononuclear cell (PBMC) cultures was higher inNMOpatients than in healthy controls and the level of IL-21 produced by peripheral blood CD4 T cell cultures was positively correlated to expanded disability status scale (EDSS) score…”
ResultBlood–Brain Barrier Disruption in Neuroimmunological Disease
Shimizu, F., & Nakamori, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910625 · Cited by 75
“Interactions between pathogenic T cells and B cells in the presence of IL-6, IL-23, and TGF-β differentiate into Th17 cells, which secrete IL-17, promote endothelial activation, and increase trans-endothelial migration of neutrophils and eosinophils [106,117,118].”
BackgroundSaggau, C., Bacher, P., Esser, D., Rasa, M., Meise, S., Mohr, N., Kohlstedt, N., Hutloff, A., Schacht, S.-S., Dargvainiene, J., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.005 · Cited by 79
The Gut Microbiome in Neuromyelitis Optica
Zamvil, S. S., Spencer, C. M., Baranzini, S. E., & Cree, B. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0594-z · Cited by 74
Immunopathogenesis of Neuromyelitis Optica
Levy, M., Wildemann, B., Jarius, S., Arellano, B., Sasidharan, S., Weber, M. S., & Stüve, O. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800100-4.00006-4 · Cited by 66
Restoring immune tolerance in neuromyelitis optica: Part II
Bar‐Or, A., Steinman, L., Behne, J. M., Benítez‐Ribas, D., Chin, P. S., Clare-Salzler, M. J., Healey, D. G., Kim, J. I., Kranz, D. M., Lutterotti, A., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000277 · Cited by 57
Misra, R. S., Shah, S. M. Z. S., Fowell, D. J., Wang, H., Scheible, K. M., Misra, S. K., Huyck, H. L., Wyman, C. P., Ryan, R. M., Reynolds, A. M., et al. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.03.007 · Cited by 55
“In other chronic inflammatory states, increased IL-6 production by CD4+ non-regulatory T cells (non-Tregs) has been reported [27-29].”
BackgroundKong, B. S., Kim, Y., Kim, G. Y., Hyun, J., Kim, S., Jeong, A., & Kim, H. J. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0961-z · Cited by 57
“Recent reports suggest that upon activation with LPS, NMOSD monocytes produce higher amounts of inflammatory cytokines such as IL-12, IL-23, and IL-6 compared to healthy controls (HC) [8].”
BackgroundTh17 cells in neuromyelitis optica spectrum disorder: a review
Lin, J., Li, X., & Xia, J. (2016) · International Journal of Neuroscience · doi:10.3109/00207454.2016.1163550 · Cited by 53
“One study [19] reported that IL-21 secreted by CD4+ T cells was associated with neurological disability and that these cytokines may act on humoral immunity.”
InfluentialResolution of inflammation in neuromyelitis optica spectrum disorders
Wang, X., Jiao, W., Lin, M., Lu, C., Liu, C., Wang, Y., Ma, D., Wang, X., Yin, P., Feng, J., et al. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.09.040 · Cited by 48
IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis
Ghalamfarsa, G., Mahmoudi, M., Mohammadnia‐Afrouzi, M., Yazdani, Y., Anvari, E., Hadinia, A., Ghanbari, A., Setayesh, M., Yousefi, M., & Jadidi‐Niaragh, F. (2015) · Journal of Immunotoxicology · doi:10.3109/1547691x.2015.1089343 · Cited by 49
“There is evidence implying IL-21 modulates the selfreactive immune responses in various CNS-related autoimmune diseases (Petrelli et al. 2011; Yoshizaki et al. 2012; Linhares et al. 2013; Liu et al., 2015).”
Neuromyelitis optica and neuromyelitis optica spectrum disorders
Marignier, R., Cobo Calvo, A., & Vukusic, S. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000455 · Cited by 45
Restoring immune tolerance in neuromyelitis optica: Part I
Steinman, L., Bar‐Or, A., Behne, J. M., Benítez‐Ribas, D., Chin, P. S., Clare-Salzler, M. J., Healey, D. G., Kim, J. I., Kranz, D. M., Lutterotti, A., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000276 · Cited by 43
“In NMO/SD, the pathogenic antibody response is dominated by class-switched IgG, indicating an underlying AQP4-reactive T cell activity.(27,28) In addition, Th17 polarization of naive T cells leads to the secretion of proinflammatory cytokines in relation to target lesions, including interleukin (IL)-17A and granulocyt…”
BackgroundMichael, B. D., Elsone, L., Griffiths, M. J., Faragher, B. E., Borrow, R., Solomon, T., & Jacob, A. (2013) · Cytokine · doi:10.1016/j.cyto.2013.07.019 · Cited by 41
Immunoinflammatory diseases of the central nervous system – the tale of two cytokines
Hofer, M. J., & Campbell, I. L. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13175 · Cited by 42
“In addition, other immunopathogenic pathways have been identified that are implicated in the pathogenesis of NMO such as T-cell-mediated immunity, principally involving Th17 cells (Linhares et al., 2013).”
BackgroundBiomarkers for neuromyelitis optica
Chang, K., Ro, L., Lyu, R., & Chen, C. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.11.004 · Cited by 39
What’s new in neuromyelitis optica? A short review for the clinical neurologist
Whittam, D. H., Wilson, M., Hamid, S. H. M., Keir, G., Bhojak, M., & Jacob, A. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8445-8 · Cited by 43
Effect of DMARDs on the immunogenicity of vaccines
van Sleen, Y., van der Geest, K. S. M., Huckriede, A. L. W., van Baarle, D., & Brouwer, E. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00992-8 · Cited by 43
Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects
Waliszewska‐Prosół, M., Chojdak-Łukasiewicz, J., Budrewicz, S. P., & Pokryszko‐Dragan, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062801 · Cited by 43
“Complex interplay of T-cells and B-cells in this process includes presentation of relevant antigens, dynamic balance between Th17 and Treg (with downregulation of the latter), secretion of proinflammatory cytokines and stimulation of B-cells expansion and proliferation [8,11,21,22].”
BackgroundIncreased Soluble C 5b‐9 in CSF of Neuromyelitis Optica
Wang, H., Wang, K., Wang, C., Qiu, W., Lu, Z., & Hu, X. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12132 · Cited by 39
Maciak, K., Pietrasik, S., Dziedzic, A., Redlicka, J., Saluk, J., Bijak, M., Wlodarczyk, T. W., & Miller, E. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168946 · Cited by 37
Xie, H., Zhao, Y., Pan, C., Zhang, J., Zhou, Y., Li, Y., Duan, R., Yao, Y., Gong, Z., Teng, J., et al. (2021) · BMC Neurology · doi:10.1186/s12883-021-02432-0 · Cited by 36
Hofer, L. S., Ramberger, M., Gredler, V., Pescoller, A. S., Rostásy, K., Sospedra, M., Hegen, H., Berger, T., Lutterotti, A., & Reindl, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01188 · Cited by 30
Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders
Wang, X., Yi, H., Liu, J., Li, M., Mao, Z., Xu, L., & Peng, F. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.04.039 · Cited by 30
A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder
Ghafouri‐Fard, S., Azimi, T., & Taheri, M. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737673 · Cited by 29
Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis
Li, Y., Rauniyar, V. K., Yin, W., Hu, B., Ouyang, S., Xiao, B., & Yang, H. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1460-3 · Cited by 35
“In Neuromyelitis Optica patients, the release of IL-21 by CD4? activated T cells correlated positively with neurological disability of the diseases [9].”
BackgroundThe role and mechanisms of Microglia in Neuromyelitis Optica Spectrum Disorders
Li, W., Liu, J., Tan, W., & Zhou, Y. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.61153 · Cited by 30
“5 response in NMO patients is positively correlated with neurological disability [21].”
BackgroundNeutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD
Lin, J., Xue, B., Li, J., Xu, H., Huang, X., Yao, Z., Li, X., & Xia, J. (2017) · Neurological Sciences · doi:10.1007/s10072-017-3068-5 · Cited by 31
Barros, P. O., Linhares, U. C., Teixeira, B., Kasahara, T. M., Ferreira, T. B., Alvarenga, R. M. P., Hygino, J., Silva-Filho, R. G., Bittencourt, V. C. B., de Andrade, R. M., et al. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.06.016 · Cited by 26
Self-citationKim, Y., Kim, S. Y., Han, S.-M., Payumo, R. M. P., Park, K., Kim, H. E., Kim, S., Hyun, J., Lee, E., & Kim, H. J. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abk2132 · Cited by 26
“The release of interleukin-6 (IL-6) and IL-21 by polyclonally activated CD4+ T cells derived from patients with NMOSD correlated with neurological disability (9).”
Dias, A. S. O., Sacramento, P. M., Lopes, L. M. F., Sales, M. C., Castro, C., Araújo, A. C. R. A., Ornelas, A. M. M., Aguiar, R. S., Silva-Filho, R. G., Alvarenga, R., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.06.018 · Cited by 20
Self-citationAther, J. L., Fortner, K. A., Budd, R. C., Anathy, V., & Poynter, M. E. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.327 · Cited by 20
Li, X., & Zhao, C. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103826 · Cited by 23
Liang, S., Qin, Q., Tang, Y., Liao, W., Yang, Y., He, J., & Li, L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2019.12.12 · Cited by 19
“(22) reported enhanced cell death in PHA-activated cultures from NMO patients and low release of interleukin-2 (IL-2) and interferon-gamma (INF-γ).”
BackgroundYu, M., Shi, Z., Zhang, W., Zhu, L. D., Tang, S., Chen, H., Wang, X., Du, Q., Li, S. C., Zhang, Y., et al. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200134 · Cited by 19
Rosso, M., Saxena, S., & Chitnis, T. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1757434 · Cited by 19
Cho, E. B., Min, J., Cho, H., Seok, J. M., Lee, H. L., Shin, H. Y., Lee, K. H., & Kim, B. J. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.09.039 · Cited by 17
Exploring the complex interplay: gut microbiome, stress, and leptospirosis
Petakh, P., Oksenych, V., Kamyshna, I. I., Boisak, I., Lyubomirskaya, K., & Kamyshnyi, O. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1345684 · Cited by 18
Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future
Lin, J., Xue, B., Li, X., & Xia, J. (2016) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1242587 · Cited by 15
Bo, M., Niegowska, M., Arru, G., Sechi, E., Mariotto, S., Mancinelli, C. R., Farinazzo, A., Alberti, D., Gajofatto, A., Ferrari, S., et al. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.02.013 · Cited by 15
“…al., 2012; Vincent et al., 2008), astrocyte dysfunction and damage (Hinson et al., 2012; Rossi et al., 2012; Takano et al., 2010), T cell activation (Linhares et al., 2013; Vaknin-Dembinsky et al., 2012; Varrin-Doyer et al., 2012) and demyelinating processes (Marignier et al., 2010; Sharma et al.,…”
BackgroundUnbalanced Expression of ICOS and PD-1 in Patients with Neuromyelitis Optica Spectrum Disorder
Xue, Q., Li, X., Gu, Y., Wang, X., Wang, M., Tian, J., Duan, X., Gao, H., Ji, X., Yan, X., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50479-4 · Cited by 17
Xu, L., Xu, H., & Tang, C. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01325 · Cited by 18
“Furthermore, AQP4-sensitized T-cells, including AQP4-specific Th17 cells, can compromise the BBB integrity via interleukin (IL)-17 secretion, causing endothelial activation and transendothelial migration of neutrophils (Linhares et al., 2013; Mills, 2023).”
BackgroundSmith, K. J., Minns, D., McHugh, B. J., Holloway, R. K., O’Connor, R. A., Williams, A., Melrose, L. A., McPherson, R. C., Miron, V. E., Davidson, D. J., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001554 · Cited by 21
Chronic IL-21 drives neuroinflammation and promotes lipid accumulation in microglia
Oyamada, H. A. A., Ying, Y., Agrawal, S., Liu, A., Subramanian, V. S., Bento, C. A. M., & Agrawal, A. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00510-2 · Cited by 15
Self-citationThe Role of Gut Microbiota in Neuromyelitis Optica Spectrum Disorder
Yao, S., Yang, X., Cen, L., & Tan, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063179 · Cited by 13
“IL-6 and IL-21 released by CD4 + T cells from NMO patients have been directly linked to neurologic dysfunction [70], and the in vivo level of IL-6 was higher at a 2-year follow-up in relapsed NMO patients [71].”
BackgroundDixit, P., Garg, R. K., Malhotra, H. S., Jain, A., Verma, R. K., Sharma, P., & Kumar, N. (2015) · Inflammation Research · doi:10.1007/s00011-015-0896-8 · Cited by 12
“Estimation in patients with neuromyelitis optica has suggested that IL-6 by polyclonally activated CD4 ? T cells directly correlated to neurological disability [13].”
Emerging functions and therapeutic targets of IL‐38 in central nervous system diseases
Gao, Y., Cai, L., Wu, Y., Jiang, M., Zhang, Y., Ren, W., Song, Y., Li, L., Lei, Z., Wu, Y., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14550 · Cited by 12
Li, X., Zhou, Q., Yang, W. B., Xiong, X., Du, R., & Zhang, J. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9860-3 · Cited by 11
“One possible explanation suggests that the candidates by which the CD4 effector T cell influence on CD8 T cells may be mediated include CD40–CD40L interactions between the different cell types, required for CD4 T cell help of CD8 T cells [38, 39], and the cytokines IL-12, IL-6, and IL-21, all of which have been implic…”
BackgroundRocca, M. A., Cacciaguerra, L., & Filippi, M. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1764352 · Cited by 11
Research and progress on biomarkers of neuromyelitis optica spectrum disorders
Wang, J., Liu, J., Li, R., & Wang, C. (2020) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2020.1830109 · Cited by 11
“Since T cells are required for B cells to produce antibodies [48], researchers [49,50] detected T cell subsets and cytokines of NMOSD patients and found that in AQP4-IgG (þ) NMOSD Th17 cells can secrete more pro-inflammatory cytokines IL-6 and IL-21.”
BackgroundRole of interleukin‐6 in the pathogenesis of neuromyelitis optica
Uzawa, A., Mori, M., & Kuwabara, S. (2013) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12024 · Cited by 11
Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse
Farber, R. S., Gross, R., Zakin, E., & Fabian, M. T. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516670736 · Cited by 9
Zhang, J.-W., Li, Y.-F., Zhou, Y.-Q., Wang, K., Pan, C.-M., Zhao, Y., Xie, H.-J., Duan, R., Gong, Z., & Jia, Y.-J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.763793 · Cited by 6
“Activated monocytes promote the production of inflammatory cytokines, such as tumor necrosis factor α, interleukin (IL)-6, IL-1β, IL-12, and IL23 (38), and increase the expression of costimulatory molecules, such as CD80, ICAM-1, and HLA-DR (39), whereas the level of”
BackgroundKang, H., Li, H., Ai, N., Liu, H., Xu, Q.-G., Tao, Y., & Wei, S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.589288 · Cited by 5
“The release of IL-6 and IL-21 by polyclonally activated CD4+ T cells obtained from NMO patients was shown to have direct correlations with neurological disability (14).”
BackgroundNeuromyelitis optica spectrum disorder: an overview
Ramakrishnan, P., & Nagarajan, D. (2020) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2020-023 · Cited by 5
“Several researchers who have an‑ alysed the cytokine levels in NMOSD found IL‑6, IL‑17, IL‑21 and IL‑1β, the Th17 cytokines to be elevated in majority of the cases (Ishizu et al., 2005; Wang et al., 2011; Herges et al., 2012; Wu et al., 2012; Linhares et al., 2013; Barros et al., 2015).”
BackgroundType I Interferon Signaling Augments Autoimmunity in Neuromyelitis Optica Spectrum Disorder
Zhang, T., Yang, X., Gao, X., Du, X., Lian, X., Shao, N., Liu, Y., Huang, Z., Jia, D., Lau, A. Y. L., et al. (2025) · Advanced Science · doi:10.1002/advs.202500942 · Cited by 5
The Roles of Regulatory T Cells in Central Nervous System Autoimmunity
Keating, B. A., Lees, J. G., & Moalem‐Taylor, G. (2019) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-19515-1_6 · Cited by 4
Niu, X., & Chen, G. (2011) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.s1-008 · Cited by 3
“The release of IL-6 as well as IL-21 by polyclonal activated CD4+ T cells was directly correlated to neurological disability, which may be the reason for NMO patients’ being more refractory to corticoid treatment [68].”
BackgroundInflammatory Demyelinating Diseases of the Central Nervous System
Li, M., & Liu, Q. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_8 · Cited by 4
Oki, S. (2014) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12128 · Cited by 2
“First, production of IL-6 and IL-21 by CD4+ T cells ex vivo is shown to be directly associated with neurological disability in NMO patients.(80) In addition, higher concentrations of serum IL-21 were observed in NMO patients,(81) and concentrations of IL-21 protein in cerebrospinal fluid were significantly”
BackgroundFazlinejad, N., Hosseini, S., Yaghoobpoor, S., Dehghani, M., Bazrafshan, H., Khanzadeh, S., & Lucke-Wold, B. P. (2023) · Journal of Physical Medicine and Rehabilitation · doi:10.33696/rehabilitation.5.035 · Cited by 1
“Meanwhile, higher IL-6 levels in the CSF of NMOSD patients may promote the survival of AQP4-specific Th17 cells while inhibiting FOXP3+ regulatory T cells [67].”
BackgroundInfluentialThe Roles of Regulatory T Cells in Central Nervous System Autoimmunity
Keating, B. A., Lees, J. G., & Moalem‐Taylor, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_6 · Cited by 1
Pfeuffer, S., & Wiendl, H. (2016) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-016-1586-y
“Die Bildung von IL-6 geschieht durch eine spezielle Gruppe von T-Zellen, den 17-Zellen [32].”
BackgroundRojas, N. J. R., Tobón, A. C. N., & Amórtegui, L. A. C. (2021) · Revista Cuarzo · doi:10.26752/cuarzo.v27.n1.521
Correale, J. D., & Marrodán, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-24297-7_10-1
Correale, J. D., & Marrodán, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_10
NMOSD : Adaptive Immunity Revisited
Akatani, R., & Chihara, N. (2025) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.70030 · Cited by 1
The epithelial-dendritic cell interface in pulmonary disease
Ather, J. L. (2014) · Research Publications (Maastricht University) · doi:10.26481/dis.20140213ja
Metadata
- Authors
- Linhares, U. C., Schiavoni, P. B., Barros, P. O., Kasahara, T. M., Teixeira, B., Ferreira, T. B., Alvarenga, R., Hygino, J., Vieira, M. M. M., Bittencourt, V. C. B., Andrade, R. M., Andrade, A. F., & Bento, C. A. M.
- Affiliations
- Universidade Federal do Estado do Rio de Janeiro (BR)
- Universidade do Estado do Rio de Janeiro (BR)
- Corresponding author
- Bento, Cleonice A. M.
- ORCID
- Venue
- Journal of Clinical Immunology
- Published
- 2012-09-05
- Volume
- 33
- Issue
- 1
- Pages
- 179-189
- ISSN
- 0271-9142 (ISSN-L)
- 1573-2592
- OpenAlex
- W1993219034
- Cited by
- 78
- References
- 57
- Citations by year
- 2025: 4 · 2024: 10 · 2023: 3 · 2022: 1 · 2021: 9 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 6 · 2013: 8
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neuromyelitis optica, CD4+ T cells, interleukin-6, IL-21, IL-17, Th17 cells, Th1 cytokines, neurological deficit, glucocorticoid resistance, T cell proliferation, IL-23, optic neuritis, myelitis, autoimmune central nervous system disease
- MeSH terms
- Interleukin-21, Adult, Cells, Cultured, Female, Humans, Interleukins, Lymphocyte Activation, Male, Middle Aged, Neuromyelitis Optica, CD4-Positive T-Lymphocytes, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.